NSC35862 | 5069-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: NSC35862
• 英文别名: 2-Amino-6-pentylthiopurin；6-pentylsulfanyl-7(9)H-purin-2-ylamine；6-pentylsulfanyl-7H-purin-2-amine
• CAS: 5069-66-9
• 化学式: C₁₀H₁₅N₅S
• 分子量: 237.329
• InChiKey: SQEYMSWFUJWJJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Lung-Targeted Drugs
  申请人：Hostetler Karl Y.

  公开号：US20080221061A1

  公开（公告）日：2008-09-11

  Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.

  本发明提供了一种用于治疗肺部疾病的方法和组合物，包括但不限于感染和小细胞和非小细胞肺癌，通过将感兴趣的药物与甘油醚或甘油磷酸酯结合。
• 6-ETHER/THIOETHER-PURINES AS TOPOISOMERASE II CATALYTIC INHIBITORS AND THEIR USE IN THERAPY
  申请人：Jensen Lars Hollund

  公开号：US20090209535A1

  公开（公告）日：2009-08-20

  The present invention relates to certain purines of the following formulae, which act as topoisomerase II catalytic inhibitors: wherein: J is independently: —H or —NR N1 R N2 ; X is independently: —O—, or —S—; Q is independently: a covalent bond, C 1-7 alkylene, C 2-7 alkenylene, C 2-7 alkynylene, C 3-7 cycloalkylene, C 3-7 cycloalkenylene, or C 3-7 cycloalkynylene; T is independently: a group A 1 or a group A 2 ; A 1 is independently: C 6-14 carboaryl, C 5-14 heteroaryl, C 3-12 carbocyclic, or C 3-12 heterocyclic; and is independently unsubstituted or substituted; A 2 is independently: —H, —CN, —OH, or —O(C═O)—C 1-7 alkyl; R N is independently —H or a nitrogen ring substituent; R 8 is independently —H or a ring substituent; either: each of R N1 and R N2 is independently —H or a nitrogen substituent; or: R N1 and R N2 taken together with the nitrogen atom to which they are attached form a ring having from 3 to 7 ring atoms; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. These compounds are useful in combination with topoisomerase II poisons, such as anthracyclines and epipodophyllotoxins, in the treatment of proliferative conditions (e.g., cancer). These compounds are also useful in the treatment of tissue damage associated with extravasation of a topoisomerase II poison, such as an anthracycline or an epipodophyllotoxin.
• LUNG-TARGETED DRUGS
  申请人：Hostetler Karl Y.

  公开号：US20120122818A1

  公开（公告）日：2012-05-17

  Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.
• US8101745B2
  申请人：——

  公开号：US8101745B2

  公开（公告）日：2012-01-24
• US8318700B2
  申请人：——

  公开号：US8318700B2

  公开（公告）日：2012-11-27